BD (Becton, Dickinson and Company) has appointed Shawn Bevec as Senior Vice President of Investor Relations, effective January 20, 2026. Bevec will report to Interim CFO Vitor Roque and will lead all communications of BD’s strategic progress and shareholder-value initiatives. He joins from Quest Diagnostics, where he directed investor communications and capital-markets engagement, and brings prior experience as a sell-side analyst covering health care services and medical devices at Deutsche Bank and Susquehanna International Group. His scientific background includes R&D roles at Pfizer and Johnson & Johnson. Bevec holds a B.S. in Chemistry from the University of Arizona and an MBA from NYU’s Stern School. Investors should see strengthened transparency on BD’s growth drivers as the company pursues its long-term strategy across medical essentials and biopharmaceutical systems.

BD is committing $110 million to establish BD Neopak™ Glass Prefillable Syringe production at its Columbus, Nebraska facility, with operations expected to start mid-2026. The investment comprises $100 million for syringe manufacturing capacity—supporting formats from 1 mL to 2.25 mL and compatibility with high-viscosity biologics and GLP-1 therapies—and $10 million to enhance cannula production. The expansion will create approximately 120 new jobs and build on a prior $35 million project that added 50 positions for prefilled flush syringes. These measures reinforce BD’s Pharmaceutical Systems portfolio by localizing critical components, improving supply resilience for injectable biologics and combination products, and supporting the company’s plan to invest more than $2.5 billion in U.S. manufacturing over five years.